Better than RECIST and faster than iRECIST: defining the Immunotherapy Progression Decision score to better manage progressive tumors on immunotherapy.
Younes BelkouchiHugues TalbotNathalie LassauLittisha LawranceSiham FarhaneRahma Feki-MkaouarJoya HadchitiLama DawiJulien VibertPaul-Henry CournedeClara CousteixCamille MazzaMichèle KindAntoine ItalianoAurélien MarabelleSamy AmmariStephane ChampiatPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
The iPD score provides oncologists with a new evaluation, computable at first-progression, to decide if treatment should be continued (for the GP group), or immediately changed for the PP and CP groups. Further validation on larger cohorts is needed to prove its efficacy in clinical practice.